The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.g

Pulmonary fibrosis

A cause and effect relationship is difficult to prove in RA, since pulmonary fibrosis is part of the manifestations of the rheumatoid lung

Publications

Díez Piña JM, Vázquez Gómez O, Mayoralas Alises S, García Jiménez JD, Alvaro Alvarez D, Rodríguez Bolado MP

[Etanercept as a possible trigger of fatal pulmonary fibrosis].

Archivos de bronconeumologia 2008 Jul;44;393-5 — 2008 Jul — 393-5

Hagiwara K, Sato T, Takagi-Kobayashi S, Hasegawa S, Shigihara N, Akiyama O

Acute exacerbation of preexisting interstitial lung disease after administration of etanercept for rheumatoid arthritis.

The Journal of rheumatology 2007 May;34;1151-4 — 2007 May — 1151-4

Lindsay K, Melsom R, Jacob BK, Mestry N

Acute progression of interstitial lung disease: a complication of etanercept particularly in the presence of rheumatoid lung and methotrexate treatment.

Rheumatology (Oxford, England) 2006 Aug;45;1048-9 — 2006 Aug — 1048-9

Tengstrand B, Ernestam S, Engvall IL, Rydvald Y, Hafström I

[TNF blockade in rheumatoid arthritis can cause severe fibrosing alveolitis. Six case reports].

Lakartidningen 2005 Dec 5-11;102;3788-90, 3793 — 2005 Dec 5-11 — 3788-90, 3793